HIV-related lymphomas

Curr Opin Oncol. 2022 Sep 1;34(5):439-445. doi: 10.1097/CCO.0000000000000890. Epub 2022 Jul 27.

Abstract

Purpose of review: To summarize the recent evidence on the pathology, current standard of care and recent advances in the treatment of HIV-related lymphomas.

Recent findings: Lymphomas remain a major cause of morbidity and mortality in people living with HIV, even in the era of combination antiretroviral therapy (cART). However, treatment outcomes for these malignancies have improved in recent decades, due to full-dose chemotherapy, effective cART and supportive care. Recent advances include the identification of novel driving signaling pathways as promising molecular targets to improve lymphoma outcomes.

Summary: Patients with HIV-related lymphomas who receive effective cART should be treated like the general population.

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • HIV Infections* / drug therapy
  • Humans
  • Lymphoma, AIDS-Related* / drug therapy
  • Neoplasms* / drug therapy
  • Treatment Outcome